| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18794104 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 105 journal articles in the PubMed database | Email to a friend | | |
| Négrier S, Perol D, Ravaud A, et al.
Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFN{alpha} in Patients with Good Prognosis Metastatic Renal Cancer. [JOURNAL ARTICLE]
Clin Cancer Res 2008 Sep 15; 14(18):5907-5912.
Abstract | Full Citation | Find Related Articles | | Ravaud A, Delva R, Gomez F, et al.
Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
Cancer 2002 Dec 1; 95(11):2324-30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Tourani JM, Pfister C, Berdah JF, et al.
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Clin Oncol 1998 Jul; 16(7):2505-13.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Henriksson R, Nilsson S, Colleen S, et al.
Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Br J Cancer 1998 Apr; 77(8):1311-7.
Abstract | Full Citation | Find Related Articles | | May M, Helke C, Bock M, et al.
[Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil] [Evaluation Studies, Journal Article]
Urologe A 2004 Sep; 43(9):1111-9.
Abstract | Full Citation | Find Related Articles | | Boccardo F, Rubagotti A, Canobbio L, et al.
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial]
Tumori 1998 Sep-Oct; 84(5):534-9.
Abstract | Full Citation | Find Related Articles | | Tourani JM, Pfister C, Tubiana N, et al.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Clin Oncol 2003 Nov 1; 21(21):3987-94.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Dutcher JP, Logan T, Gordon M, et al.
Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
Clin Cancer Res 2000 Sep; 6(9):3442-50.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Négrier S, Caty A, Lesimple T, et al.
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 2000 Dec 15; 18(24):4009-15.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
